Intravitreal Triamcinolone in Diabetic Retinopathy

Author(s): Maximino J. Abraldes, Maribel Fernandez, Francisco Gomez-Ulla.

Journal Name: Current Diabetes Reviews

Volume 5 , Issue 1 , 2009

Submit Manuscript
Submit Proposal

Abstract:

Diabetic macular edema is an important cause of visual loss in the developed world and may frequently lead to irreversible changes in visual acuity. The Early Treatment Diabetic Retinopathy Study showed a significant benefit in using focal laser photocoagulation for the treatment of macular edema, more specifically defined as clinically significant macular edema. However, some cases of diabetic macular edema are refractory to laser therapy and do not have a good prognosis with such treatment. Triamcinolone acetonide is glucocoticosteroid with antiangiogenic and antiedematous properties. Recently, some promising results, respect to the increases of visual acuity and decreases in foveal thickness, have been shown in different studies for the treatment of refractory diabetic macular edema with intravitreal triamcinolone acetonide.

Keywords: Intravitreal triamcinolone, Diabetic macular edema, Diabetic retinopathy, Vitrectomy

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 5
ISSUE: 1
Year: 2009
Page: [18 - 25]
Pages: 8
DOI: 10.2174/157339909787314185

Article Metrics

PDF: 15